Group 1 - The successful inclusion of Baiaosaitu in the Hong Kong Stock Connect marks a significant milestone in the company's capital market development, indicating a new stage in capital accessibility, market recognition, and long-term investment value [1][3] - Baiaosaitu is an international biotechnology company driven by innovative technology for new drug development, focusing on "high-quality source molecule acquisition" and "high-certainty in vivo validation" as its core processes, supported by a leading global platform of "full human antibody library + target humanized mouse library" [2] - The inclusion of H-shares in the Hong Kong Stock Connect allows eligible domestic institutional and individual investors to directly invest in Baiaosaitu's H-shares through the Shanghai and Shenzhen Stock Exchanges [3] Group 2 - The H-share inclusion in the Hong Kong Stock Connect represents a systemic breakthrough in the capital market and will create a more efficient synergy with the company's A-share Sci-Tech Innovation Board platform, further supporting the company's ongoing investments in technology platform transformation, global business expansion, and long-term strategic implementation [5] - Baiaosaitu aims to maintain a technology innovation-oriented approach, deepen its global cooperation network, and steadily enhance operational quality and communication with the capital market, while committing to a more open, transparent, and stable posture to reward long-term investors [5] - The company is positioned as a "global source of new drugs," contributing long-term value to the high-quality development of China's biopharmaceutical industry and global innovation [5]
再迎里程碑！百奥赛图H股成功纳入港股通